Authors/Disclosures
|
Christopher Goetz, MD, FAAN
(Rush University Medical Center)
|
The institution of Dr. Goetz has received research support from Michael J. Fox Foundation. The institution of Dr. Goetz has received research support from NIH. The institution of Dr. Goetz has received research support from Department of Defense. Dr. Goetz has received publishing royalties from a publication relating to health care. Dr. Goetz has received publishing royalties from a publication relating to health care. Dr. Goetz has received publishing royalties from a publication relating to health care. |
|
Damiano M. Rovituso
(University of Wuerzburg)
|
No disclosure on file |
|
Jeffery Vance, MD, PhD
(University of Miami)
|
Dr. Vance has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for neurology genetics. |
|
Karen Nuytemans, PhD
(U of Miami, John P. Hussman Institute)
|
The institution of Dr. Nuytemans has received research support from NIH. The institution of Dr. Nuytemans has received research support from NIH. The institution of Dr. Nuytemans has received research support from Department of Defense. The institution of Dr. Nuytemans has received research support from Margaret Q. Landenberger Foundation. The institution of Dr. Nuytemans has received research support from American Parkinson Disease Association. The institution of Dr. Nuytemans has received research support from Florida Department of Health. |
|
|
No disclosure on file |
|
William K. Scott, MD
(Univ of Miami Miller School of Medicine)
|
No disclosure on file |
|
Gary W. Beecham, PhD
(University of Miami, Hussman Institute for Human Genomics)
|
The institution of Dr. Beecham has received research support from NIH. The institution of an immediate family member of Dr. Beecham has received research support from NIH. |
|
Roy L. Freeman, MD
(Beth Israel Deaconess Hosp)
|
Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regenacy. Dr. Freeman has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurobo. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli-Lilly. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Inhibikase. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Freeman has stock in Neurobo. Dr. Freeman has stock in Cutaneous NeuroDiagnostics. The institution of Dr. Freeman has received research support from NIH. The institution of Dr. Freeman has received research support from Theravance. The institution of Dr. Freeman has received research support from Biohaven. The institution of Dr. Freeman has received research support from Lundbeck. |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Stephen K. Van Den Eeden, PhD
(Kaiser Permanente)
|
Dr. Van Den Eeden has received personal compensation for serving as an employee of Kaiser Permanente Northern California. The institution of Dr. Van Den Eeden has received research support from NIH. The institution of Dr. Van Den Eeden has received research support from Biogen. The institution of Dr. Van Den Eeden has received research support from MJFF. The institution of an immediate family member of Dr. Van Den Eeden has received research support from NIH. |